NEW YORK, Dec. 8, (GenomeWeb News) - Under a collaborative agreement, XCeleron will provide Servier accelerator mass spectrometry services to study candidate drugs in humans, Xceleron said yesterday.
Servier will accelerate drug development by testing candidate drugs in phase 0 microdose studies instead of waiting for conventional phase 1 studies.
The 12-month rolling agreement allows the pharmaceutical company to include early human studies as part of its drug candidate selection process, Xceleron said.
Financial details were not disclosed.